GlassScriptPhysician profile
Brian Y Dong
NPI 1366837874
$31,492.91
in general payments reported to CMS, 2019-2025
61 companies · $10K in 2025
The $10K reported for 2025 was more than what 89% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $1,062 · 2020: $1,210 · 2021: $2,223 · 2022: $5,063 · 2023: $2,594 · 2024: $9,184 · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $11K · Food and Beverage: $10K · Education: $149 · Long Term Medical Supply Or Device Loan: $99.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $11,472.50 |
| Food and Beverage | $10,213.74 |
| Education | $149.21 |
| Long Term Medical Supply Or Device Loan | $99.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $8,917.74 | 2019-2025 | Lynparza, Truqap, Enhertu |
| Pfizer INC. | $5,799.16 | 2019-2025 | |
| Daiichi Sankyo INC. | $4,587.38 | 2020-2025 | Enhertu, Datroway, Injectafer |
| Novartis Pharmaceuticals Corporation | $1,663.17 | 2021-2025 | Kisqali |
| Amgen INC. | $1,328.24 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $1,319.83 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Gilead Sciences, INC. | $1,037.14 | 2021-2025 | Trodelvy |
| Incyte Corporation | $924.84 | 2020-2025 | Jakafi, Monjuvi, Pemazyre |
| Regeneron Healthcare Solutions, INC. | $452.57 | 2019-2025 | Libtayo |
| Genzyme Corporation | $451.48 | 2019-2025 | |
| Stemline Therapeutics INC. | $449.43 | 2023-2025 | Orserdu, Elzonris |
| Lilly USA, LLC | $443.41 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Seagen INC. | $398.76 | 2021-2023 | Tukysa, Adcetris |
| E.R. Squibb & Sons, L.L.C. | $378.58 | 2019-2025 | Opdivo |
| Eisai INC. | $304.92 | 2020-2025 |
Show all 58 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $259.14 | 2020-2025 | |
| Rigel Pharmaceuticals, INC. | $225.06 | 2020-2024 | Tavalisse, Rezlidhia |
| Puma Biotechnology, INC. | $185.33 | 2023-2025 | |
| Astellas Pharma US INC | $175.06 | 2019-2025 | Cresemba, Vyloy, Xospata |
| Glaxosmithkline, LLC. | $161.72 | 2021-2025 | Ojjaara |
| Takeda Pharmaceuticals U.S.A., INC. | $141.43 | 2019-2025 | Fruzaqla, Alunbrig |
| Bayer Healthcare Pharmaceuticals INC. | $129.65 | 2021-2025 | |
| Beigene USA, INC. | $126.86 | 2021-2023 | Brukinsa |
| Janssen Biotech, INC. | $112.46 | 2021-2024 | Darzalex, Rybrevant, Imbruvica |
| Coherus Oncology, INC. | $102.80 | 2023-2024 | |
| Emd Serono, INC. | $102.20 | 2020-2022 | |
| Array Biopharma INC | $94.89 | 2023-2025 | Lorbrena, Mektovi, Braftovi |
| Deciphera Pharmaceuticals INC. | $86.39 | 2021-2025 | Qinlock, Romvimza |
| Jazz Pharmaceuticals INC. | $81.58 | 2019-2023 | |
| Mirati Therapeutics, INC. | $80.63 | 2023-2024 | Krazati |
| Geron Corporation | $78.10 | 2025 | Rytelo |
| Alexion Pharmaceuticals, INC. | $71.59 | 2024-2025 | Ultomiris |
| Pharmacosmos Therapeutics INC. | $71.32 | 2022-2024 | Cosela |
| G1 Therapeutics, INC. | $68.16 | 2023 | Cosela |
| Taiho Oncology, INC. | $62.06 | 2023-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $56.43 | 2019 | |
| Celgene Corporation | $54.87 | 2023-2025 | Reblozyl |
| Foundation Medicine, INC. | $51.20 | 2022-2023 | Foundationone Cdx |
| Genentech USA, INC. | $48.93 | 2024-2025 | Itovebi, Tecentriq |
| Sumitomo Pharma America, INC. | $46.95 | 2024-2025 | Orgovyx |
| Tersera Therapeutics LLC | $38.06 | 2024-2025 | Zoladex |
| Springworks Therapeutics, INC. | $34.81 | 2024 | Ogsiveo |
| Ipsen Biopharmaceuticals, INC | $26.88 | 2019-2022 | |
| Iovance Biotherapeutics, INC. | $26.80 | 2025 | Amtagvi |
| Nuvation Bio INC. | $24.20 | 2025 | Ibtrozi |
| Celltrion USA INC. | $21.60 | 2025 | Vegzelma |
| Tempus Ai, INC | $19.71 | 2024 | |
| Cumberland Pharmaceuticals, INC. | $17.56 | 2024 | Sancuso |
| Abbvie INC. | $17.27 | 2021 | |
| Beone Medicines USA, INC. | $17.17 | 2025 | Brukinsa |
| Organon LLC | $16.61 | 2022 | |
| Novo Nordisk INC | $15.97 | 2019 | |
| Kite Pharma, INC. | $15.75 | 2024 | Yescarta |
| Global Blood Therapeutics, INC. | $15.65 | 2022 | |
| Sobi, INC | $14.70 | 2023 | |
| Apellis Pharmaceuticals, INC. | $13.72 | 2022 | |
| Karyopharm Therapeutics INC. | $13.04 | 2020 | |
| Kyowa Kirin, INC. | $11.95 | 2021 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$660.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Dong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.